

December 24, 2015  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President & Chief Executive Officer

**SymBio Files Supplemental NDA for TREAKISYM®  
in a 25mg Vial (Different Strength)**

TOKYO, Japan, December 24, 2015 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio,”) announced today its submission of a supplemental New Drug Application (“sNDA”) to the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan for TREAKISYM® (“bendamustine”) in respect of a 25mg vial.

Submission of this sNDA will not impact the Company’s financial forecast for FY2015.

**[Contact]**

**Investor Relations**

Tel: +81 (0)3 5472 1125

**[Glossary]**

**About Bendamustine Hydrochloride (TREAKISYM®)**

In partnership with Eisai Co., Ltd., SymBio received marketing approval for TREAKISYM® (SyB L-0501) in October, 2010, to treat Japanese patients with relapsed/refractory (r/r) low-grade non-Hodgkin’s lymphoma (Lg-NHL) and mantle cell lymphoma (MCL).

**About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus on oncology, hematology and pain management.